Scholar Rock Holding Corporation · NASDAQ:SRRK

Scholar Rock — 44th Annual J.P. Morgan Healthcare Conference (January 2026)

31 slides from Scholar Rock's conference presentation, Jan 12, 2026

1. Slide 1: 44th Annual J.P. Morgan Healthcare Conference Scholar Rock Investor Presentation

   © 2026 Scholar Rock, Inc. All rights reserved. 44th Annual J.P. Morgan Healthcare Conference Scholar Rock Investor Presentation JANUARY 12, 2026 Exhibit 99.2

2. Slide 2: Forward-Looking Statements

   © 2026 Scholar Rock, Inc. All rights reserved. 2 Forward-Looking Statements Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, “Scholar Rock”), including without limitation, Scholar

3. Slide 3: Scholar Rock is in a position of strength entering 2026

   © 2026 Scholar Rock, Inc. All rights reserved. SHAPING THE FUTURE OF TREATMENT FOR PATIENTS LIVING WITH RARE NEUROMUSCULAR DISEASES (NMDs) INITIATE PHASE 2 STUDY for apitegromab in facioscapulohumeral muscular dystrophy SRK-439 DOSING COMMENCED in Phase 1 healthy volunteer study ONGOING MID - 2026 A

4. Slide 4: Apitegromab poised to usher in next phase of innovation in SMA

   © 2026 Scholar Rock, Inc. All rights reserved. INITIAL PHASE OF INNOVATION: MOTOR NEURON NEXT PHASE OF INNOVATION: MUSCLE 4 Apitegromab poised to usher in next phase of innovation in SMA Targeting muscle ‒ the principal organ affected in SMA NOTE: Apitegromab and SRK-439 launch expectations followin

5. Slide 5: Powering Scholar Rock through the end of this decade and into next

   © 2026 Scholar Rock, Inc. All rights reserved. ~35,000 SMA patients have received an approved SMN-targeted therapy1-3 Powering Scholar Rock through the end of this decade and into next High SMA diagnosis rates and accelerated time to treatment 5 Global apitegromab opportunity in SMA alone offers pot

6. Slide 6: Poised for 2026 U.S. launch of apitegromab, followed by Europe

   © 2026 Scholar Rock, Inc. All rights reserved. 6 Poised for 2026 U.S. launch of apitegromab, followed by EMA approval and launch in Europe, beginning with Germany NOTE: Following regulatory approval(s). Building a 50-country platform to serve patients with rare, severe neuromuscular diseases United

7. Slide 7: Shaping the future of treatment for patients living with rare neuromuscular disease

   © 2026 Scholar Rock, Inc. All rights reserved. 7 Shaping the future of treatment for patients living with rare neuromuscular disease IV, Intravenously; SC, Subcutaneously. THERAPEUTIC TARGET INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL APITEGROMAB Selective anti-latent myostatin antibod

8. Slide 8: Scholar Rock 2026 priorities

   © 2026 Scholar Rock, Inc. All rights reserved. 8 Scholar Rock 2026 priorities 1. Subject to regulatory approval(s). NMDs, neuromuscular diseases. Focused execution and financial discipline 1 COMMERCIALIZE Commercialize apitegromab for treatment of patients with SMA1 BLA resubmission and U.S. launch,

9. Slide 9: Commercialize Apitegromab for Treatment of Patients with SMA

   © 2026 Scholar Rock, Inc. All rights reserved. Commercialize Apitegromab for Treatment of Patients with SMA Transforming the treatment of SMA with muscle-targeted therapy 9

10. Slide 10: SMN-targeted therapies do not target muscle

    © 2026 Scholar Rock, Inc. All rights reserved. ...but do not target muscle SMN-Targeted Therapies slow further degeneration of motor neurons1 Apitegromab has the potential to directly target progressive muscle atrophy and weakness Muscle-Targeted Treatment Spinal Muscular Atrophy Muscle atrophy and

11. Slide 11: Addressing progressive muscle weakness: apitegromab positioned as future standard-of-care

    © 2026 Scholar Rock, Inc. All rights reserved. ~35,000 patients have received an approved SMN-targeted therapy1-3 ~7,000 patients have received an approved SMN-targeted therapy4 GLOBAL SMA OPPORTUNITY 90% of patients with SMA rate muscle strength and motor function as top unmet needs5 1 1 Addressing

12. Slide 12: Apitegromab successful in Phase 3 SMA study

    © 2026 Scholar Rock, Inc. All rights reserved. 1 2 Apitegromab successful in Phase 3 SMA study First and only myostatin inhibitor with a positive, statistically significant Phase 3 outcome Sources: Long KK, et al. Hum Mol Genet. 2019;28:1076-1089; Pirruccello-Straub M, et al. Sci Rep. 2018;8:2292. H

13. Slide 13: Apitegromab potential first and only muscle-targeted treatment to improve motor function in SMA

    © 2026 Scholar Rock, Inc. All rights reserved. Apitegromab has potential to be the FIRST and ONLY muscle-targeted treatment to improve motor function in SMA 30.0% vs 12.5% 30.0% of apitegromab patients ACHIEVED ≥3PT IMPROVEMENT IN HFMSE1 compared to 12.5% on SMN2- targeted treatment alone +1.8 HFMSE

14. Slide 14: Apitegromab BLA resubmission and U.S. launch anticipated in 2026

    © 2026 Scholar Rock, Inc. All rights reserved. 1 4 Apitegromab BLA resubmission and U.S. launch, following approval, anticipated in 2026 BLA, Biologics License Application; OAI, Official Action Indicated Tech transfer ongoing at second fill-finish facility; commercial capacity reserved beginning in

15. Slide 15: U.S. commercial field team focused on engagement and disease education

    © 2026 Scholar Rock, Inc. All rights reserved. >2,600 SMA Prescribers Prescribers and SMA Treatment Centers 1 5 U.S. commercial field team focused on engagement, disease education across SMA stakeholder landscape Broaden and deepen engagement Patient Advocacy National & Regional Payers Educating on

16. Slide 16: Launch readiness in Europe ahead of mid-2026 EMA decision

    © 2026 Scholar Rock, Inc. All rights reserved. 1 6 Strong momentum with apitegromab launch readiness in Europe in advance of mid-2026 EMA decision EMA, European Medicines Agency; KOL, Key Opinion Leader. Large opportunity to serve SMA patients in Europe Key leadership hires made and additional offer

17. Slide 17: Apitegromab in SMA represents a large global opportunity

    © 2026 Scholar Rock, Inc. All rights reserved. Apitegromab in SMA represents a large global opportunity to serve patients 1. Revenue as of Biogen 3Q25 financial update, Roche 3Q25 financial update, and Novartis 3Q25 financial update; 2. Scholar Rock internal estimates as of December 2025. SMN, survi

18. Slide 18: Develop Apitegromab for Patients with SMA Under 2 and Additional NMDs

    © 2026 Scholar Rock, Inc. All rights reserved. Develop Apitegromab for Patients with SMA Under 2 and for Additional Neuromuscular Diseases (NMDs) Building a pipeline -in - a -product to reach more patients with SMA and with additional rare, severe NMDs 1 8

19. Slide 19: Ongoing Phase 2 OPAL study in infants and toddlers with SMA

    © 2026 Scholar Rock, Inc. All rights reserved. Evaluating PK, PD, efficacy, safety, and tolerability of apitegromab over 48 weeks 1 9 Furthering our commitment to broad SMA community Ongoing Phase 2 OPAL study evaluating apitegromab in infants and toddlers with SMA PK, Pharmacokinetic, PD, Pharmacod

20. Slide 20: FSHD: Rare, devastating NMD with significant unmet need

    © 2026 Scholar Rock, Inc. All rights reserved. 2 0 FSHD: Rare, devastating NMD with significant unmet need >30,000 patients diagnosed in U.S. and Europe; no approved therapies 1. Tawil R, et al. Skelet Muscle. 2014;4:12; 2. Hubregtse L, et al. Neuromuscul Disord. 2024;36:6-15; 3. Tihaya MS, et al. N

21. Slide 21: Preclinical studies provide mechanistic rationale for apitegromab in FSHD

    © 2026 Scholar Rock, Inc. All rights reserved. 2 1 Preclinical studies provide mechanistic rationale for apitegromab in FSHD Increased muscle mass, strength, and endurance in gold standard FLExDUX4 mouse model of FSHD *Muscle mass=weight of tibialis anterior muscle; muSRK-015P is a murine version of

22. Slide 22: Phase 2 trial evaluating apitegromab in patients with FSHD

    © 2026 Scholar Rock, Inc. All rights reserved. KEY ELIGIBILITY CRITERIA • Aged 18-60 years • Genetically confirmed FSHD1 or FSHD2 • Clinical severity score of 1.5 to 3.0 • Baseline 10 MWRT time ≤5 seconds Apitegromab (10mg/kg IV Q4W) Placebo (IV Q4W) PRIMARY ENDPOINT: Mean lean muscle volume (LMV) c

23. Slide 23: Unlocking pipeline-in-a-product with apitegromab in additional rare NMDs

    © 2026 Scholar Rock, Inc. All rights reserved. 2 3 Unlocking pipeline-in-a-product with apitegromab in additional rare NMDs, beginning with FSHD Broad landscape of potential indications supports significant opportunity for muscle-targeted therapies Scholar Rock deploying innovative, world-leading an

24. Slide 24: Advance world-leading anti-myostatin pipeline

    © 2026 Scholar Rock, Inc. All rights reserved. 2 4 NEXT PHASE OF INNOVATION: MUSCLE 2026 Apitegromab U.S. launch SRK-439 global launch 2030+ SC Apitegromab global launch Apitegromab European launch Apitegromab global expansion Advance World-Leading Anti-Myostatin Pipeline Driving continued innovatio

25. Slide 25: Subcutaneous apitegromab demonstrated favorable bioavailability

    © 2026 Scholar Rock, Inc. All rights reserved. 2 5 Subcutaneous apitegromab demonstrated favorable bioavailability, with pharmacodynamic profile comparable to IV administration Source: Scholar Rock internal data. PD, pharmacodynamic. Phase 1 study comparing intravenous (IV) and subcutaneous (SC) api

26. Slide 26: Advancing anti-myostatin platform with SRK-439

    © 2026 Scholar Rock, Inc. All rights reserved. 2 6 Advancing Scholar Rock’s innovative anti-myostatin platform with SRK-439 SRK-439 is a novel, investigational myostatin inhibitor. muSRK-015P is a murine version of apitegromab. Leveraging world-leading expertise to drive continued innovation 0.0001

27. Slide 27: SRK-439 Phase 1 study and key milestones

    © 2026 Scholar Rock, Inc. All rights reserved. N≈76 Healthy Adult Participants PART A PART B 2 7 SRK-439 Phase 1 study assessing safety, tolerability, and PK/PD profile SRK-439 program key milestones 2 7 IND cleared in November 2025 Dosing commenced in Phase 1 study in December 2025 On track to repo

28. Slide 28: Financials & Upcoming Milestones

    © 2026 Scholar Rock, Inc. All rights reserved. Financials & Upcoming Milestones 2 8

29. Slide 29: Fortified balance sheet in 2025, strong cash position entering 2026

    © 2026 Scholar Rock, Inc. All rights reserved. 2 9 Fortified balance sheet in 2025, strong cash position entering 2026 Operating with financial discipline to achieve Scholar Rock’s ambitions Financial information as of December 31, 2025 has not been audited and has been prepared by, and is the respo

30. Slide 30: Scholar Rock 2026 Priorities

    © 2026 Scholar Rock, Inc. All rights reserved. 3 0 Scholar Rock 2026 Priorities Poised to be next global biotech powerhouse 1. Upon U.S. FDA approval. NMDs, neuromuscular diseases. Driving value through focused execution and financial discipline 1 COMMERCIALIZE Commercialize apitegromab for treatmen

31. Slide 31: For more information, please contact

    © 2026 Scholar Rock, Inc. All rights reserved. For more information, please contact: ir@scholarrock.com media@scholarrock.com Or visit us at www.scholarrock.com 3 1

Scholar Rock Holding — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix